Wondering if Nuvation Bio at around 8.66 is still a smart buy after its big run, or if most of the upside is already priced in? This article is designed to unpack that value question in plain English.

Nuvation Bio (NUVB) has quietly turned into one of the market’s stronger biotech movers, with the stock up about 78% over the past month and more than tripling year to date. See our latest analysis ...

Baystreet.ca News Commentary – The FDA issued multiple breakthrough approvals for oncology drugs in November 2025, marking a transformative month for cancer treatment with ...

Fintel reports that on December 11, 2025, HC Wainwright & Co. maintained coverage of Nuvation Bio (NYSE:NUVB) with a Buy ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

The average one-year price target for Nuvation Bio (NYSE:NUVB) has been revised to $10.65 / share. This is an increase of ...

Nuvation Bio Inc (NUVB) stock reached a notable milestone, hitting a 52-week high of $8.24, with shares currently trading at $8.23. This achievement marks a significant increase in investor confidence ...

Dongfang Liu, Chief Medical Officer of Nuvation Bio Inc. (NASDAQ:NUVB), sold 150,000 shares of Class A Common Stock on December 1, 2025. The sales were executed at a weighted-average price of $7.8217, ...

Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM ESTCompany ParticipantsDavid Hung - Founder, President, ...

TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease ...